Vigabatrin, the GABA‐transaminase inhibitor, damages cone photoreceptors in rats

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Annals of Neurology

• Publication date

  2004-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/ana.20081
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• γ-Vinyl GABA: comparison of neurochemical and anticonvulsant effects in mice

  2005cited by this paper
• Evidence supportive of a functional discrimination between photopic oscillatory potentials as revealed with cone and rod mediated retinopathies

  2004cited by this paper
• Dark adaptation is faster in pigmented than albino rats

  2003cited by this paper
• High‐affinity GABA uptake in retinal glial (Müller) cells of the guinea pig: Electrophysiological characterization, immunohistochemical localization, and modeling of efficiency

  2002cited by this paper
• Progressive retinal degeneration and dysfunction in R6 Huntington's disease mice.

  2002cited by this paper
• Neurotoxic effects of GABA‐transaminase inhibitors in the treatment of epilepsy: ocular perfusion and visual performance

  2002cited by this paper
• Long-term effects of light damage on the retina of albino and pigmented rats.

  2002cited by this paper
• Animal models of retinal detachment and reattachment: identifying cellular events that may affect visual recovery

  2002cited by this paper
• Vigabatrin effect on inner retinal function.

  2001influential reference
• Vigabatrin protects against hippocampal damage but is not antiepileptogenic in the lithium-pilocarpine model of temporal lobe epilepsy.

  2001cited by this paper
• Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V).

  2001cited by this paper
• The GABAC receptors of retinal neurons.

  2001cited by this paper
• Visual field constriction: Accumulation of vigabatrin but not tiagabine in the retina

  2001cited by this paper
• Visual Field Constriction in Children With Epilepsy on Vigabatrin Treatment

  2000cited by this paper
• Müller cell outgrowth after retinal detachment: association with cone photoreceptors.

  2000cited by this paper
• Targeted disruption of Müller cell metabolism induces photoreceptor dysmorphogenesis

  2000cited by this paper
• GABA and GABAA receptor antagonists alter developing cone photoreceptor development in neonatal rabbit retina

  2000cited by this paper
• Vigabatrin reduces epileptiform activity in brain slices from pharmacoresistant epilepsy patients.

  2000cited by this paper
• The relationship of MS to physical trauma and psychological stress: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

  2000cited by this paper
• Visual function loss from vigabatrin. effect Of stopping the drug

  2000influential reference
• Vigabatrin: A Novel Therapy for Seizure Disorders

  1999cited by this paper
• Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects

  1999cited by this paper
• Limiting photoreceptor death and deconstruction during experimental retinal detachment: the value of oxygen supplementation.

  1999cited by this paper
• Visual field defects associated with vigabatrin therapy

  1999cited by this paper
• Symptomatic and asymptomatic visual loss in patients taking vigabatrin.

  1999influential reference
• Vigabatrin-associated retinal cone system dysfunction

  1998cited by this paper
• Neurochemical development of the degenerating rat retina

  1997cited by this paper
• Accumulation of gamma-aminobutyric acid in diabetic rat retinal Müller cells evidenced by electron microscopic immunocytochemistry.

  1996cited by this paper
• A double-blind, placebo-controlled study of Vigabatrin three g/day in patients with uncontrolled complex partial seizures

  1996cited by this paper
• Treatment with vigabatrin may mimic alpha-aminoadipic aciduria.

  1996cited by this paper
• Treatment with Vigabatrin May Mimic α‐Aminoadipic Aciduria

  1996cited by this paper
• Excitatory Actions of GABA after Neuronal Trauma

  1996cited by this paper
• Effects of Müller cell disruption on mouse photoreceptor cell development.

  1995cited by this paper
• Ionic mechanisms of neuronal excitation by inhibitory GABAA receptors

  1995cited by this paper
• Identification and functional characterization of a dual GABA/taurine transporter in the bullfrog retinal pigment epithelium

  1995cited by this paper
• Dye‐induced photolesion in the mammalian retina: Glial and neuronal reactions

  1993cited by this paper
• GABAergic mechanisms in the pathogenesis and treatment of epilepsy.

  1989cited by this paper
• Vigabatrin in the treatment of epilepsy in children.

  1989cited by this paper
• Immunocytochemical evidence that vigabatrin in rats causes GABA accumulation in glial cells of the retina.

  1989influential reference
• A Study of the Effects of Vigabatrin on the Central Nervous System and Retina of Sprague Dawley and Lister-Hooded Rats

  1987cited by this paper
• Toxic effects of DL-alpha-aminoadipic acid on müller cells from rats in vivo and cultured cerebral astrocytes.

  1982cited by this paper
• The oscillatory potentials of the mudpuppy retina.

  1978cited by this paper
• γ‐VINYL GABA (4‐amino‐hex‐5‐enoic acid), A NEW SELECTIVE IRREVERSIBLE INHIBITOR OF GABA‐T: EFFECTS ON BRAIN GABA METABOLISM IN MICE 1

  1977cited by this paper

• Melatonin alleviates retinal injury induced by vigabatrin and partially enhances its antiepileptic effects.

  2025cites this paper
• Taurine: a promising nutraceutic in the prevention of retinal degeneration

  2023cites this paper
• Testing for pharmacogenomic predictors of ppRNFL thinning in individuals exposed to vigabatrin

  2023cites this paper
• Metabolism and Functions of Amino Acids in Sense Organs.

  2020cites this paper
• Taurine Protects Retinal Cells and Improves Synaptic Connections in Early Diabetic Rats

  2020cites this paper
• An investigation of the ocular toxic effects of levetiracetam therapy in children with epilepsy

  2019cites this paper
• Design and Mechanism of GABA Aminotransferase Inactivators. Treatments for Epilepsies and Addictions.

  2018cites this paper
• 15th Annual Meeting of the Safety Pharmacology Society: Focus on traditional sensory systems.

  2017cites this paper
• Comprehensive review of visual defects reported with topiramate

  2017cites this paper
• Evaluation of inner retinal layers with optic coherence tomography in vigabatrin-exposed patients

  2017cites this paper
• The Vigabatrin Induced Retinal Toxicity is Associated with Photopic Exposure and Taurine Deficiency: An In Vivo Study

  2016cites this paper
• Quantitative and Topographical Analysis of the Losses of Cone Photoreceptors and Retinal Ganglion Cells Under Taurine Depletion.

  2016cites this paper
• How blood barrier stands up to drug treatments

  2016cites this paper
• The effects of taurine on vigabatrin, high light intensity and mydriasis induced retinal toxicity in the pigmented rat.

  2015cites this paper
• Association Between Electroretinogram-identified Vigabatrin Toxicity and Subsequent Visual Field Reduction

  2014cites this paper
• The Eye and Ear

  2014cites this paper
• Taurine Deficiency and the Eye

  2014cites this paper
• Vigabatrin prevents seizure in swine subjected to hyperbaric hyperoxia.

  2013cites this paper
• Taurine is a crucial factor to preserve retinal ganglion cell survival.

  2013cites this paper
• Evaluation of the taurine concentrations in dog plasma and aqueous humour: a pilot study.

  2013cites this paper
• (1S, 3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115), a potent γ-aminobutyric acid aminotransferase inactivator for the treatment of cocaine addiction.

  2012cites this paper
• Retinal and cochlear toxicity of drugs: new insights into mechanisms and detection.

  2012cites this paper
• Electrophysiological evaluation of retinal function in children receiving vigabatrin medication.

  2011cites this paper
• Retinal nerve fiber layer thickness in Vigabatrin‐exposed patients

  2011cites this paper
• Retinal Origins of Vigabatrin Toxicity in Infantile Spasms

  2011cites this paper
• Modelling the topography of absolute defects in patients exposed to the anti-epileptic drug vigabatrin and in normal subjects using automated static suprathreshold perimetry of the entire 80° visual field

  2011cites this paper
• Reduced grating acuity associated with retinal toxicity in children with infantile spasms on vigabatrin therapy.

  2009cites this paper
• Evaluating Risks for Vigabatrin Treatment

  2009cites this paper
• Dose-related changes in retinal function and PKC-alpha expression in rabbits on vigabatrin medication

  2009cites this paper
• The management of drug resistant seizures in tuberous sclerosis

  2009cites this paper
• Full-field ERG and visual fields in patients 5 years after discontinuing vigabatrin therapy

  2008cites this paper
• Retinal nerve fibre layer characteristics with vigabatrin-associated visual field loss—could scanning laser polarimetry aid diagnosis?

  2008cites this paper
• The negative ERG: clinical phenotypes and disease mechanisms of inner retinal dysfunction.

  2008cites this paper
• Panretinal, high-resolution color photography of the mouse fundus.

  2007cites this paper
• Tiagabine and vigabatrin reduce the severity of NMDA-induced excitotoxicity in chick retina

  2006cites this paper
• Retinal Function in Rabbits Does Not Improve 4–5 Months after Terminating Treatment with Vigabatrin

  2006cites this paper
• Inhibition of rabbit brain 4-aminobutyrate transaminase by some taurine analogues: a kinetic analysis.

  2006cites this paper
• Vigabatrin Retinopathy in an Irish Cohort: Lack of Correlation with Dose

  2006cites this paper
• Ophthalmologic and neurologic findings in two children exposed to vigabatrin in utero.

  2005cites this paper
• Dogma and dreams: experimental lessons for epilepsy mechanism chasers

  2005cites this paper
• Topical Review: Intractable Seizures in Tuberous Sclerosis Complex: From Molecular Pathogenesis to the Rationale for Treatment

  2004cites this paper
• Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII).

  2004cites this paper